Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis
Issued Date
2024-12-01
Resource Type
ISSN
20955162
eISSN
20499957
Scopus ID
2-s2.0-85212678433
Journal Title
Infectious Diseases of Poverty
Volume
13
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Infectious Diseases of Poverty Vol.13 No.1 (2024)
Suggested Citation
Qin M., Yang G., Yan J., Wang L., Feng Y., Wang D., Wang Q., Hou Y., Zhao J., Lei J., Wang Z., Jiang M., Yu C., Gavotte L., Frutos R. Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis. Infectious Diseases of Poverty Vol.13 No.1 (2024). doi:10.1186/s40249-024-01268-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102548
Title
Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis
Author's Affiliation
Interactions Hôtes-Vecteurs-Parasites-Environnement Dans les Maladies Tropicales Négligées dues aux Trypanosomatides (INTERTRYP)
Observation Spatiale, Modèles & Science Impliquée
Chinese Center for Disease Control and Prevention
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Gansu Provincial Center for Disease Control and Prevention
Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention
Beijing Chaoyang District Center for Disease Prevention and Control
Sichuan Provincial Center for Disease Control and Prevention
Observation Spatiale, Modèles & Science Impliquée
Chinese Center for Disease Control and Prevention
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Gansu Provincial Center for Disease Control and Prevention
Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention
Beijing Chaoyang District Center for Disease Prevention and Control
Sichuan Provincial Center for Disease Control and Prevention
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Echinococcosis is an infectious parasitic disease that is extremely harmful to human health. Albendazole is provided free of charge to patients requiring medication under the central government finance transfer payment scheme for echinococcosis control and prevention in China. Our aim is to monitor the state of patient medication and its therapeutic impact, which will help improve medication compliance and the therapeutic effect. Methods: Random cluster sampling was used to select 10 echinococcosis-endemic counties in China, and all albendazole-treated patients in these counties were investigated. The chi-square and Kruskal–Wallis tests were used to compare two or more rates or constituent ratios, and multiple logistic regression analysis was used to identify the influencing factors. The records of patients were reviewed to obtain the initial diagnosis results as well as the most recent follow-up results and time, and efficacy was assessed. Results: We examined 899 patient files treated with albendazole in 10 endemic counties. Of the 582 evaluable files, 7.9% did not take albendazole, and 69.2% did not take albendazole regularly. Only 22.9% took albendazole regularly. Of the 536 patients who took albendazole, 242 exhibited adverse reactions. Patients who were Tibetan, herdsmen, received no formal education, used emulsion, and exhibited adverse reactions demonstrated poor compliance. A total of 174 patients with cystic echinococcosis received their most recent imaging follow-up results within one year of the investigation date. Among them, 9 patients met the criteria for cure, accounting for 5.2%; 56 patients showed effectiveness, accounting for 32.2%; 105 patients were deemed ineffective, accounting for 59.8%; 5 patients experienced recurrence, accounting for 2.9%. Conclusions: Albendazole medication compliance in patients with echinococcosis is not ideal. We must prioritize health education and promotion for Tibetans, herdsmen, and those without formal education. Patients who adhered to their medication regimen achieved higher rates of cure and effectiveness. To improve medication compliance and efficacy, it is particularly important to improve communication and medication guidance for patients receiving emulsions and those with adverse reactions after taking albendazole. Simultaneously strengthen patients' attention to follow-up and re-examination.